miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris
Jan 05, 2018 12:01 pm UTC| Business
BOULDER, Colo., Jan. 05, 2018 -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has...
ABcann Appoints New Chief Marketing Officer
Jan 05, 2018 12:01 pm UTC| Business
NAPANEE, Ontario, Jan. 05, 2018 -- ABCANN GLOBAL CORPORATION (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce the appointment of Sung Kang as the Company's Chief Marketing Officer (CMO). Mr. Kang, who...
ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018
Jan 05, 2018 12:01 pm UTC| Business
Geneva, Switzerland and Boston, MA - January 5, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that...
Jan 05, 2018 12:00 pm UTC| Business
- Pivotal AdAPT Study of Oral Brincidofovir for Adenovirus Now Enrolling - - No GI Adverse Effects for IV Brincidofovir 10 mg - - Announces First Antiviral Specific for Norovirus Now In Clinical Testing - DURHAM,...
Dentsply Sirona to Present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 05, 2018 12:00 pm UTC| Business
YORK, Pa., Jan. 05, 2018 -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (NASDAQ:XRAY), The Dental Solutions Company™, today announced that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on...
Blue Line Responds to U.S. Attorney General Statement Regarding Cannabis Industry Enforcement
Jan 05, 2018 12:00 pm UTC| Business
Denver, CO, Jan. 05, 2018 -- Blue Line Protection Group, Inc. (OTCPink: BLPG) is reiterating its commitment to ensuring the legal cannabis industry operates in a safe, secure and compliant manner, in light of the recent...
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018
Jan 05, 2018 12:00 pm UTC| Business
ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as first indication ...